FULL SUPPLEMENT: Optimizing Transungal Efficacy at the Site of the Infection With Efinaconazole

September 2023 | Volume 22 | Issue 9 | SF378719s5 | Copyright © September 2023


Published online August 29, 2023

Naiem T. Issa MD PhDa, Leon Kircik MDb

aForefront Dermatology, Vienna, VA; Issa Research and Consulting, LLC, Springfield, VA
bIcahn School of Medicine at Mount Sinai, New York, NY; Physicians Skin Care, PLLC, Louisville, KY;
DermResearch, PLLC, Louisville, KY; Skin Sciences, PLLC, Louisville, KY

Abstract
Onychomycosis is a prevalent condition affecting the United States and global population. Treatment options are limited, with only 3 topical anti-fungal medications garnering approval in the US within the last 25 years: ciclopirox, tavaborole, and efinaconazole. The economic impact and quality of life burden due to onychomycosis are high. Here we provide an up-to-date review of all approved topical anti-fungal therapies for toenail onychomycosis. We discuss treatment efficacies, pharmacology, and use in special populations, as well as current evidence for complementary and alternative medicine.

J Drugs Dermatol. 2023;22:9(Suppl 1):s5-10.
In this supplement:

Updated Review of Topical Pharmaceuticals and Complementary and Alternative Medications for the Treatment of Onychomycosis in Both General and Special Populations in the United States
Onychomycosis is an infection of the nail bed or nail plate by fungal organisms. These organisms are predominantly dermatophytes and less commonly yeasts, but recent research revealed an increasing prevalence of non-dermatophyte molds and mixed infection. It is highly prevalent in North America, affecting at least 13% of the population. In addition, underrepresented groups (eg, Blacks, Hispanics) exhibit a disproportionately high burden of onychomycosis after adjusting for variables such as concomitant tinea pedis, diabetes mellitus, immune compromise, nail psoriasis, and insurance status.

Read the article here.
Close Menu